Johnson Pharmacare Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 233635, "name": "Johnson Pharma", "stock_name": "Johnson Pharma", "full_name": "Johnson Pharmacare Ltd", "name_url": "stocks-analysis/johnson-pharma", "exchange": 0, "exchangecode": "", "primexch": 0, "country_id": 34, "currency": "INR", "cmp": "0.50", "chg": "0.00", "chgp": "0.00%", "dir": 0, "prev_price": "0.50", "mcapval": "28.00 Cr", "mcap": "Micro Cap", "scripcode": 532154, "symbol": "", "ind_name": "Diversified Commercial Services", "ind_code": 49, "sector_id": 17, "indexname": "India SENSEX", "isin": "INE560F01022", "curr_date": "Jun 24, 03:30 PM", "curr_time": "23:05 PM", "last_traded_at": "Jun 24, 03:30 PM IST", "bse_nse_vol": "3.94 lacs", "exc_status": "Active", "traded_date": "Jun 24, 2026", "traded_date_str": "2026 06 24", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/johnson-pharma-233635-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Johnson Pharmacare Declines 1.85%: Downgrade and Weak Fundamentals Weigh", "link": "https://www.marketsmojo.com/news/stocks-in-action/johnson-pharmacare-declines-185-downgrade-and-weak-fundamentals-weigh-4053103", "imagepath": "", "date": "2026-06-14 15:00:06", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>1 June:</strong> Quality grade downgraded to Below Average, highlighting fundamental weaknesses</p>\n <p><strong>1 June:</strong> MarketsMOJO assigns Strong Sell rating amid weak fundamentals and bearish technicals</p>\n <p><strong>5 June:</strong> Week closes at Rs.0.53, down 1.85% for the week</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.0.54</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.0.53</div><div class=\"stat-change negative\">-1.85%</..." }, { "title": "Johnson Pharmacare Ltd Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals", "link": "https://www.marketsmojo.com/news/stock-recommendation/johnson-pharmacare-ltd-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-technicals-4025236", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/JohnsonPharmaca_mojoScore_4025236.png", "date": "2026-06-01 08:03:05", "description": "Johnson Pharmacare Ltd has been assigned a Strong Sell rating by MarketsMOJO as of 29 May 2026, reflecting deteriorating fundamentals and a bearish technical outlook. The downgrade from a previously ungraded status is driven by a comprehensive reassessment across quality, valuation, financial trend, and technical parameters, signalling heightened risk for investors in this micro-cap stock." }, { "title": "Johnson Pharmacare Ltd Quality Grade Downgrade Highlights Fundamental Weaknesses", "link": "https://www.marketsmojo.com/news/stocks-in-action/johnson-pharmacare-ltd-quality-grade-downgrade-highlights-fundamental-weaknesses-4024917", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/JohnsonPharmaca_qualitydot_4024917.png", "date": "2026-06-01 08:00:17", "description": "Johnson Pharmacare Ltd has recently undergone a significant downgrade in its quality grading, shifting from a non-qualifying status to a below average rating as of 29 May 2026. This change reflects deteriorating business fundamentals, particularly in profitability, capital efficiency, and financial stability, raising concerns for investors amid a challenging market backdrop." }, { "title": "Johnson Pharmacare Q4 FY26: Alarming ₹55.61 Crore Loss Raises Serious Viability Concerns", "link": "https://www.marketsmojo.com/news/result-analysis/johnson-pharmacare-q4-fy26-alarming-5561-crore-loss-raises-serious-viability-concerns-4022172", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/JohnsonPharmaca_quaterlyResult_4022172.png", "date": "2026-05-29 17:04:35", "description": "Johnson Pharmacare Limited reported a catastrophic fourth quarter for FY26, posting a net loss of ₹55.61 crores in Q4 FY26—a dramatic deterioration from the ₹0.51 crore loss in Q4 FY25. The micro-cap diversified commercial services company, with a market capitalisation of just ₹30.00 crores, continues to generate zero revenue whilst accumulating substantial losses, raising fundamental questions about operational viability and business sustainability." } ], "total": 84, "sid": "233635", "stock_news_url": "https://www.marketsmojo.com/news/johnson-pharmacare-233635" }, "announcements": [ { "caption": "Submission Of Audited Financials Results Of Jhonson Pharmacare Ltd. For The Quarter And Year Ended On March 31St 2026", "datetime": "19-Jun-2026", "details": "Submission of Audited Financial Results of Jhonson Pharmacare ltd for the quarter and year ended on March 31st March 2026", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer", "datetime": "12-Jun-2026", "details": "Pursuant to Regulation 30 of SEBI (LODR) Regulations 2015 there is change.", "source": "BSE" }, { "caption": "Outcome Of Meeting Of Board Of Directors Held On Wednesday 27Th May 2026 At Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.", "datetime": "01-Jun-2026", "details": "meeting of board of director to considered and approved the following 1.audited financial results 2. Statement of deviation or variation 3. take note on resignation of Rajendra prasad (Non- executive director) 4. take note on resignation of umesh kumar (executive director)", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "No <strong>Dividend</strong> history available", "data": [] }, { "img": "splits.svg", "title": "SPLITS", "msg": "", "data": [ { "txt": "Johnson Pharmacare Ltd has announced <strong>1:10</strong> stock split, ex-date: 05 Jan 22", "dt": "2022-01-05", "middle_text": "Split" } ] }, { "img": "bonus.svg", "title": "BONUS", "msg": "", "data": [ { "txt": "Johnson Pharmacare Ltd has announced <strong>1:10</strong> bonus issue, ex-date: 07 Apr 22", "dt": "2022-04-07", "middle_text": "Bonus Alert" } ] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

1 June: Quality grade downgraded to Below Average, highlighting fundamental weaknesses

1 June: MarketsMOJO assigns Strong Sell rating amid weak fundamentals and bearish technicals

5 June: Week closes at Rs.0.53, down 1.85% for the week

-1.85%Read full news article

Johnson Pharmacare Ltd Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals

2026-06-01 08:03:05

Johnson Pharmacare Ltd has been assigned a Strong Sell rating by MarketsMOJO as of 29 May 2026, reflecting deteriorating fundamentals and a bearish technical outlook. The downgrade from a previously ungraded status is driven by a comprehensive reassessment across quality, valuation, financial trend, and technical parameters, signalling heightened risk for investors in this micro-cap stock.

Read full news article

Johnson Pharmacare Ltd Quality Grade Downgrade Highlights Fundamental Weaknesses

2026-06-01 08:00:17

Johnson Pharmacare Ltd has recently undergone a significant downgrade in its quality grading, shifting from a non-qualifying status to a below average rating as of 29 May 2026. This change reflects deteriorating business fundamentals, particularly in profitability, capital efficiency, and financial stability, raising concerns for investors amid a challenging market backdrop.

Read full news article

Johnson Pharmacare Q4 FY26: Alarming ₹55.61 Crore Loss Raises Serious Viability Concerns

2026-05-29 17:04:35

Johnson Pharmacare Limited reported a catastrophic fourth quarter for FY26, posting a net loss of ₹55.61 crores in Q4 FY26—a dramatic deterioration from the ₹0.51 crore loss in Q4 FY25. The micro-cap diversified commercial services company, with a market capitalisation of just ₹30.00 crores, continues to generate zero revenue whilst accumulating substantial losses, raising fundamental questions about operational viability and business sustainability.

Read full news article